ABSTRACT Background and aims: Obese and diabetic mice display enhanced intestinal permeability and metabolic endotoxaemia that participate in the occurrence of metabolic disorders. Our recent data support the idea that a selective increase of Bifidobacterium spp. reduces the impact of high-fat diet-induced metabolic endotoxaemia and inflammatory disorders. Here, we hypothesised that prebiotic modulation of gut microbiota lowers intestinal permeability, by a mechanism involving glucagon-like peptide-2 (GLP-2) thereby improving inflammation and metabolic disorders during obesity and diabetes. Methods: Study 1: ob/ob mice (Ob-CT) were treated with either prebiotic (Ob-Pre) or non-prebiotic carbohydrates as control (Ob-Cell). Study 2: Ob-CT and Ob-Pre mice were treated with GLP-2 antagonist or saline. Study 3: Ob-CT mice were treated with a GLP-2 agonist or saline. We assessed changes in the gut microbiota, intestinal permeability, gut peptides, intestinal epithelial tight-junction proteins ZO-1 and occludin (qPCR and immunohistochemistry), hepatic and systemic inflammation. Results: Prebiotic-treated mice exhibited a lower plasma lipopolysaccharide (LPS) and cytokines, and a decreased hepatic expression of inflammatory and oxidative stress markers. This decreased inflammatory tone was associated with a lower intestinal permeability and improved tight-junction integrity compared to controls. Prebiotic increased the endogenous intestinotrophic proglucagonderived peptide (GLP-2) production whereas the GLP-2 antagonist abolished most of the prebiotic effects. Finally, pharmacological GLP-2 treatment decreased gut permeability, systemic and hepatic inflammatory phenotype associated with obesity to a similar extent as that observed following prebiotic-induced changes in gut microbiota. Conclusion: We found that a selective gut microbiota change controls and increases endogenous GLP-2 production, and consequently improves gut barrier functions by a GLP-2-dependent mechanism, contributing to the improvement of gut barrier functions during obesity and diabetes.
Obesity is typically associated with a cluster of several metabolic disorders, characterised by a lowgrade inflammation. 1 2 Evidence that the gut microbiota composition can be different between healthy and obese and/or type 2 diabetic patients has led to the investigation of this environmental element as a key factor in the pathophysiology of metabolic diseases. [3] [4] [5] We previously reported that the gut microbiota is involved in high-fat diet-induced metabolic endotoxaemia, adipose tissue inflammation and metabolic disorders. [6] [7] [8] [9] The link between high-fat diet-induced inflammation, oxidative stress, metabolic disorders, and gut microbiota, could be lipopolysaccharide (LPS)-dependent. 7 10-14 Several pieces of clinical and experimental data have confirmed that LPS significantly contributes to the development of obesity-related inflammatory liver diseases such as non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. [15] [16] [17] High plasma LPS levels could result from an increased production of endotoxin upon changes in the gut microbiota. 7 8 Normally, the intestinal epithelium acts as a continuous barrier to avoid LPS translocation; yet some endogenous or exogenous events may alter this protective function. Among the elements promoting a leaky gut, and thus an increased plasmatic LPS level, are alcohol consumption, 15 18-22 immobilisation stress, 23 24 and radiation 25 have been proposed. In addition, we have recently shown that the modulation of gut bacteria following a high-fat diet strongly increases intestinal permeability, by reducing the expression of genes coding for two tight junction proteins ZO-1 and occludin. 6 We previously reported that gut bacteria are clearly involved in these events since obese and high-fat fed-diabetic mice treated with an antibiotic recovered normal intestinal epithelial integrity. 6 Also, recent data have shown that obese and diabetic mice display enhanced intestinal permeability, and are characterised by a metabolic endotoxaemia and a low-grade inflammation. 6 7 26 Furthermore, high-fat feeding changes gut microbiota 6-8 27 towards a decreased number of bifidobacteria, 6 -8 a group of bacteria which has been shown to reduce intestinal LPS levels in mice and to improve the mucosal barrier function. [28] [29] [30] [31] [32] Besides, we have shown that feeding mice with prebiotics increased the number of intestinal bifidobacteria and reduced the impact of high-fat diet-induced metabolic endotoxaemia and inflammatory disorders. 8 33 Importantly, however, the mechanisms linking prebiotic-induced changes in gut microbiota, metabolic endotoxaemia and the improvement of obesity-related hepatic and metabolic disorders are still unknown.
By using these experiments, we have tested the hypothesis that the control of gut permeability through the selective modulation of gut microbiota by prebiotics participates in the improvement of metabolic diseases in ob/ob mice. Novel mechanisms involving the influence of gut fermentation on specific proglucagon-derived peptides -namely, glucagonlike peptide-2 (GLP-2) -are proposed.
MATERIALS AND METHODS Animals Experiment 1
Six-week-old ob/ob (n = 10/group) mice (C57BL/6 background; Jackson Laboratory, Bar Harbor, Maine, USA) were housed in a controlled environment (12 h daylight cycle, lights off at 18.00 hours) in groups of 2 mice/cage, and kept with free access to food and water. The mice were fed a control diet (Ob-CT) (A04, Villemoisson sur Orge, France), or a control diet containing a mix of a fermentable dietary fibre (oligofructose) (Ob-Pre) (Orafti, Tienen, Belgium), 33 or a diet containing a mix a nonfermentable dietary fibre (microcrystalline cellulose) (Ob-Cell) (Vivapur Microcrystalline cellulose; J. Retten Maier 38 Söhne, Weissenborn, Germany). Dietary fibres were added in a proportion of 9:1 (weight of control diet:weight of fibres).
Experiment 2
Six-week-old ob/ob (n = 8/group) mice (C57BL/6 background; Jackson Laboratory) were housed in a controlled environment (12 h daylight cycle, lights off at 18.00 hours) in groups of 2 mice/cage, and kept with free access to food and water. To study the significance of GLP-2 in this model, mice were injected subcutaneously twice daily for 4 weeks with 2.5 mg/kg of GLP-2 receptor antagonist GLP-2 (3-33) (Eurogentec, Verviers, Belgium) as described [34] [35] [36] or saline. The mice were fed a control diet and injected with saline or GLP-2 antagonist (Ob-CT and Ob-Ant, respectively), or fed the prebiotic diet and injected with saline or GLP-2 antagonist (Ob-Pre and Ob-Pre-Ant, respectively).
Experiment 3
Six-week-old ob/ob (n = 6/group) mice (C57BL/6 background; Jackson Laboratory) were housed in a controlled environment (12 h daylight cycle, lights off at 1800 hours) in groups of 2 mice/cage, and kept with free access to food and water. The mice were fed the same control diet as described in experiment 1. The mice were separated into two groups and injected subcutaneously twice daily for 12 days with 25 mg GLP-2 (1-33) (Bachem, Bubendorf, Switzerland) (Ob-GLP-2), or saline (Ob-CT). GLP-2 doses were based on previous studies describing the physiological effects (ie, the intestinotrophic properties) of the peptides. 35 
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Tissue sampling
Mice were anaesthetised (ketamine/xylazine, intraperineally, 100 and 10 mg/kg, respectively) after a 5 h period of fasting, and blood samples and tissues were harvested for further analysis. Mice were killed by cervical dislocation. Liver, caecum (full and empty), muscles (vastus lateralis), and adipose tissues (epididymal, subcutaneous and visceral) were precisely dissected and weighed. The intestinal segments (jejunum, colon) were immersed in liquid nitrogen, and stored at 280uC, for further analysis.
Microbial analysis of the caecal content of selected mice
Metagenomic DNA was extracted from the caecal content of randomly selected mice (5/group), using the QIAamp DNA stool mini kit (Qiagen, Venlo, Netherlands) according to the manufacturer's instructions. Denaturing gradient gel electrophoresis (DGGE) on total bacteria, bifidobacteria and lactobacilli were performed to study the qualitative effect of the treatment on the structure and composition of the intestinal microbial community. 40 DGGE with a 45-60% denaturant gradient were used to separate the polymerase chain reaction (PCR) products obtained with a nested approach for the 16S rRNA genes of bifidobacteria (primers BIF164f-BIF662r) and lactobacilli (SGLAB0158f-SGLAB0667). The first PCR round was followed by a second amplification with primers 338F-GC and 518R. The latter primers were also used to amplify the 16S rDNA of all bacteria on total extracted DNA. The DGGE patterns obtained were subsequently analysed using the Bionumerics software version 2.0 (Applied Maths, Sint-Martens-Latem, Belgium). 41 In brief, the calculation of the similarities was based on the Pearson (product-moment) correlation coefficient. Clustering analysis was performed using the unweighted pair group method with arithmetic mean clustering algorithm (UPGMA) to calculate the dendrograms of each DGGE gel and a combination of all gels. The latter was performed on a created composite dataset. Multidimensional scaling (MDS) analysis was used to reduce the different data of the complex DGGE patterns of one sample to one point in a threedimensional space. MDS was based on the combined information from the distance matrices of each DGGE, obtained using similarity coefficients (Pearson correlation).
Quantitative PCR (qPCR) for total bacteria (using primers PRBA338f and P518r) and specific for bifidobacteria, lactobacilli or the Eubacterium rectale/Clostridium coccoides grp. was performed to study the quantitative effect of the treatment on the composition of the intestinal microbial community as reported by Possemiers et al. 
Real-time qPCR
Total RNA from tissues was prepared using the TriPure reagent (Roche, Basel, Switzerland) as described. 33 cDNA was synthesised using a reverse transcription kit (Promega, Madison, Wisconsin, USA) from 1 mg of total RNA. qPCR was performed with a STEP one PLUS instrument and software (Applied Biosystems, Foster City, California, USA), as described. 6 Primer sequences for the targeted mouse genes are presented in supplemental table 1.
Immunofluorescence analysis of occludin and ZO-1
Jejunum segments were immediately removed, washed with PBS, mounted in embedding medium (Tissue-Tek, Sakura, Netherlands), and stored at 280uC until use. Cryosections (5 mm) were fixed in acetone at 220uC for 5 min for occludin and fixed in ethanol for 30 min at room temperature and in acetone at 220uC for 5 min for ZO-1. Non-specific background was blocked by incubation with 10% bovine serum albumin (BSA) in Tris-buffered saline (TBS) and 0.3% Triton X-100 (30 min at room temperature). Sections were incubated with rabbit anti-occludin or rabbit anti-ZO-1 (1:400 for ZO-1 and 1:100 for occludin staining; Zymed Laboratories, San Francisco, California, USA) for 2 h. Sections were washed three times for 10 min in TBS and probed with goat anti-rabbit fluorescein isothiocyante (FITC)-conjugated antibodies (1:50, Zymax; Zymed Laboratories). Slides were washed three times for 10 min in TBS and mounted in mounting medium (Vectashield; Vector Laboratories, Burlingame, California, USA). Sections were visualised on a fluorescence microscope using a 640 objective, and images were stored digitally with Leica software. As a control, slides were incubated with serial dilutions of the primary antibody to signal extinction. Two negative controls were used: slides incubated with irrelevant antibody or without primary antibody. All the stainings were performed in duplicate in non-serial distant sections, and analysed in a double-blind manner by two different investigators.
Intestinal permeability in vivo
This measure is based on the intestinal permeability towards 4000 Da fluorescent dextran-FITC (DX-4000-FITC) (FD4000; Sigma-Aldrich, St. Louis, Missouri, USA) as described. 6 43 Briefly, mice that had fasted for 6 h were given DX-4000-FITC by gavage (500 mg/kg body weight, 125 mg/ml). After 1 h and 4 h, 120 ml of blood was collected from the tip of the tail vein. The blood was centrifuged at 4uC, 12 000 g for 3 min. Plasma was diluted in an equal volume of PBS (pH 7.4) and analysed for DX-4000-FITC concentration with a fluorescence spectrophotometer (HTS-7000 Plus-plate-reader; Perkin Elmer, Wellesley, Massachusetts, USA) at an excitation wavelength of 485 nm and emission wavelength of 535 nm. Standard curves were obtained by diluting FITC-dextran in non-treated plasma diluted with PBS (1:3 v/v).
Biochemical analyses
Plasma LPS concentration was determined by using a kit based upon a Limulus amoebocyte extract (LAL kit endpoint-QCL1000; Cambrex BioScience, Walkersville, Maryland, USA), samples were diluted 1/40 to 1/100 and heated for 20 cycles of 10 min at 68uC and 10 min at 4uC. An internal control for LPS recovery was included in the calculation. Plasma cytokines (interleukin (IL) 1a, IL1b, tumour necrosis factor (TNF) a, IL6, monocyte chemoattractant protein (MCP)-1, macrophage inflammatory protein (MIP)-1a, IL10, interferon (INF) c, IL15, IL18) and gut hormones (GLP-1 (active), GIP (total), amylin (active), pancreatic polypeptide) were respectively determined in duplicate by using a Bio-Plex Multiplex kit (Bio-Rad, Nazareth, Belgium), or a mouse gut hormones panel (LincoPlex; Millipore, Brussels, Belgium), and measured by using Luminex technology (Bio-Rad Bioplex; Bio-Rad) following the manufacturer's instructions, an EIA kit (GLP-2 EIA kit) (Yanaihara Institute, Shizuoka, Japan) was used to quantify GLP-2.
Statistical analysis
Results are presented as mean with the SEM. The statistical significance of differences was analysed by one-way ANOVA followed by post hoc Bonferroni's multiple comparison test or Kruskal-Wallis for non-parametric data followed by Dunn's multiple comparison test. Data with different superscript letters are significantly different p,0.05, according to the post hoc ANOVA statistical analysis. Comparisons between GLP-2-treated mice and control mice were performed using the two-tailed Student t test. Multiple correlation analyses were assessed by the Pearson's test using GraphPad Prism version 5.00 for windows. Results were considered statistically significant when p,0.05.
RESULTS
Prebiotic treatment induces changes in the gut microbiota of ob/ ob mice
Feeding ob/ob mice with the prebiotic carbohydrates (Ob-Pre) induced significant changes in the gut microbiota of the caecum, with a higher total bacteria count, Lactobacillus spp., Bifidobacterium spp., and the C coccoides-E rectale cluster (table 1) , as compared to the control mice (Ob-CT and Ob-Cell).
Changes in the microbial community composition were also observed upon DGGE analysis of the caecal content of the different treatment groups ( fig 1A-C) . Clustering of the DGGE fingerprints for total bacteria and for the specific groups of bifidobacteria and lactobacilli, indicated, for all fingerprints, a separate cluster of the Ob-Pre mice. Secondary clustering was observed between the Ob-CT and Ob-Cell mice. Finally, multidimensional scaling (MDS) analysis, performed on the composite data set derived from the combination of all the DGGE analyses of this study (total bacteria, lactobacilli and bifidobacteria), also indicated a specific clustering pattern, depending on the treatment of the ob/ob mice. ( fig 1D) . As the distance between 2 data points in the three-dimensional MDS plot is a visual representation of the difference in the microbial community composition of the caecum of the different mice, MDS analysis provides the final confirmation that the prebiotic treatment induced important changes in the gut microbiota of the Ob-Pre mice compared to the control groups.
Changes in the gut microbiota upon prebiotic administration reduce intestinal permeability
Ob-Pre fed mice exhibited a 3-fold lower plasma DX-4000-FITC area under the curve (fig 2A) as compared to Ob-CT and ObCell mice. In accordance with the in vivo assessment of intestinal permeability, LPS levels were significantly lower in Ob-Pre mice plasma samples, as compared to the other groups ( fig 2B) . Moreover, plasma DX-4000-FITC and portal plasma LPS levels were positively and significantly correlated (fig 2B, inset), further confirming the relation between intestinal permeability and the development of metabolic endotoxaemia. Gut permeability is controlled by several specific tight-junction proteins. Among these, ZO-1 and occludin have been proposed as key markers of tight-junction integrity. 26 The prebiotic treatment increased ZO-1 and occludin mRNA in the jejunum segment ( fig 2C,F) . As previously suggested, a representative immunofluorescence assay performed on intestinal sections of wild-type C57BL/6J mice demonstrated an intact network of ZO-1 and occludin proteins which were predominantly localised along the apical cellular border. 26 In strong contrast, ZO-1 and occludin staining appears to be decreased and discontinuous in Ob-CT tissues (fig 3A,B) . Furthermore, immunohistochemical CT, Cell and Pre, respectively, refer to the selected ob/ob mice fed a normal-diet, non-prebiotic control diet or prebiotic diet.
score analysis confirmed the strong alteration of ZO-1 and occludin distribution and expression as compared to wild-type mice ( fig 2E,H) . In accordance with the mRNA analysis, prebiotic feeding improved the tight junctions, since the immunohistochemical staining of both proteins localised along the apical cellular border was higher in Ob-Pre as compared to Ob-CT and Ob-Cell mice ( fig 3A,B) . To identify whether the changes in the gut microbiota and tight-junction protein expression are associated with in vivo gut permeability, multiple correlation analysis between these parameters was performed. Indeed, a negative correlation between tight-junction proteins mRNA and plasma DX-4000-FITC was found in the jejunum segment ( fig 2D,G) , and in the colon (supplementary data 1). In addition, the caecal content of Bifidobacterium spp. and portal plasma levels of LPS showed a negative correlation (supplemental data 1), suggesting that the specific increase of bifidobacteria positively impacted the development of metabolic endotoxaemia.
Changes in the gut microbiota upon prebiotic administration are associated with improved systemic and hepatic inflammation
To study the effects of changes in the gut microbiota and improved barrier function on the one hand, and metabolic disorders on the other hand, we first assessed systemic inflammation. All plasma cytokine and chemokine concentrations were decreased in Ob-Pre mice when compared to Ob-CT and Ob-Cell mice (fig 4) . Metabolic endotoxaemia is frequently associated with hepatic inflammation, and with increased oxidative stress driving metabolic disorders. Here we found that changing the gut microbiota significantly reduced plasminogen activator inhibitor 1 (PAI-1), CD68, NADPH oxidase (NADPHox) and inducible nitric oxide synthase (iNOS) mRNA concentrations ( fig 5A,B Figure 1 Prebiotic-associated changes in the gut microbiota. DGGE fingerprint patterns of the caecal microbial community of selected ob/ob mice fed a normal-diet (Ob-CT, white symbols), nonprebiotic control diet (Ob-Cell, grey symbols) or prebiotic diet (Ob-Pre, black symbols) for 5 weeks. The DGGE profiles were constructed using primers for (A) Total bacteria (B)
ghrelin) involved in glucose homeostasis, appetite and/or body weight regulation. 8 33 44-48 Here, we found that the prebiotic treatment also modulated portal plasma gut peptides in ob/ob mice, leading to a significant increase in GLP-1 (table 2) . In addition, the glucose-dependent insulinotropic polypeptides (GIPs), another peptide associated with the development of obesity, diabetes and adiposity, was significantly decreased (table 2) . [49] [50] [51] In accordance with this, Ob-Pre mice had lower visceral, epididymal and subcutaneous adipose depots and a higher muscle mass as compared to the other groups (supplemental data 2).
This study is the first in which it is shown that, besides an effect on gut peptides, feeding prebiotics also modulated two pancreatic peptides, since it significantly increased amylin (table 2) and decreased pancreatic polypeptide (PP) as compared to Ob-CT and Ob-Cell mice (table 2) . The link between the above-mentioned peptides modulated by prebiotics and gut permeability has not been described so far. Moreover, the decrease in food intake and/or a decrease in adiposity are not involved in changes in gut permeability. Thus, we have hypothesised that GLP-2, a peptide clearly related to GLP-1 production, could link changes in gut microbiota and intestinal barrier function.
Prebiotic administration increases intestinal proglucagon mRNA and portal plasma proglucagon-derived peptide GLP-2
We and other have previously shown that changing gut microbiota by using fermentable non-digestible carbohydrate significantly increases gut weight and promotes proliferation of epithelial cells. [52] [53] [54] We have also shown -and confirmed in the present study (table 2) -that feeding mice with prebiotic doubled GPL-1 portal plasma levels. 8 33 44 45 47 48 55 56 In previous studies, the increase in GLP-1 plasma level was associated with a higher GPL-1 peptide and proglucagon mRNA expression in the (proximal) colon tissue. Interestingly, our study is the first to show that a higher proglucagon mRNA content occurs in the proximal colonas expected -and also in the jejunum (fig 6A,B) . Among the proglucagon-derived peptides, GLP-2 is co-secreted with GLP-1 and exerts an intestinotrophic effect. 39 57 58 GLP-2 enhances intestinal epithelial proliferation and reduces gut permeability, [59] [60] [61] [62] hence, we found that Ob-Pre fed mice exhibited a significant increase of plasma GLP-2 levels (table 2) . Importantly, portal plasma GLP-2 and both plasma markers of gut permeability (DX-4000-FITC and LPS) were negatively correlated (fig 6C,D) . Along the same line, intestinal proglucagon and tight-junction mRNA (ZO-1, occludin) were positively correlated (fig 6E,F) . Altogether, these data suggest that the prebiotic-induced intestinal proglucagon mRNA enhanced expression and the consequent GLP-2 production indicate that this peptide may positively impacts on gut barrier integrity.
Chronic GLP-2 antagonist treatment blunts prebiotic-induced reduction in endotoxaemia and hepatic inflammatory tone
To causally link changes in endogenous GLP-2 production upon prebiotic treatment with the improvement of metabolic endotoxaemia, and inflammatory markers, we chronically blocked GLP-2 receptor in prebiotic fed ob/ob mice by using GLP-2 antagonist.
In this second set of experiments, we confirm the data observed in the first study showing that prebiotic-induced changes in gut microbiota are linked to a significant decrease in plasma LPS levels, hepatic inflammation and oxidative stress markers such as PAI-1, CD68, NADPHox and TLR4 mRNA concentrations ( fig 7B-D,F) , and to a tendency to decrease for iNOS and TNFa mRNA concentrations (fig 7E,G) . In addition, we also confirm that the prebiotic treatment increases ZO-1 and occludin mRNA (fig 7H) and the GLP-2 precursor transcript (proglucagon mRNA) content in the jejunum (fig 7I) . Importantly, the GLP-2 antagonist completely blunts the prebiotic-induced reduction endotoxaemia ( fig 7A) . Hence, most of the prebiotic-induced changes of hepatic inflammation and oxidative stress markers are also controlled by a GLP-2-dependent mechanism. We observed that mice treated concomitantly with the prebiotic and the GLP-2 antagonist or GLP-2 antagonist alone exhibit CD68, NADPHox and TLR4 mRNA levels (fig 7B-D) similar to the control mice, except for the PAI-1 mRNA levels ( fig 7F) which remains equivalent to the prebiotic treated mice with or without GLP-2 antagonist treatment. Moreover, GLP-2 antagonist treatment completely blocked the enhanced proglucagon, ZO1 and occludin mRNA levels found in prebiotic fed mice that reach values similar to the control (fig 7H,I ).
Chronic GLP-2 pharmacological treatment lowers endotoxaemia, improves gut permeability markers, and reduces systemic and hepatic inflammation, oxidative stress and macrophage infiltration markers
To study the impact of a pharmacological GLP-2 treatment, without modulation of the gut microbiota, we treated ob/ob mice with GLP-2 for 12 days. Body weight, food intake, adiposity, liver weight were equivalent between Ob-CT mice and Ob-GLP-2 mice (supplemental data 3).
Importantly, we demonstrated that GLP-2 administration to ob/ob mice dramatically decreased plasma LPS by about 50% (fig 8A) . This was accompanied by a lower plasma inflammatory tone (IL1a, MIP-1a, MCP-1, IL10) ( fig 8B-E) ). Furthermore, as reported in both prebiotics-fed mice studies, mRNA concentrations of macrophage infiltration (TLR4, CD68) ( fig 8G,I) , inflammation (TNFa, PAI-1) (fig 8F,J) and oxidative stress (iNOS, NADPHox) markers (fig 8H,K) were decreased in Ob-GLP-2 mice as compared to Ob-CT mice. Finally, ZO-1 and occludin staining immunohistochemical score analysis confirmed the strong impact of GLP-2 on the tight-junctions proteins ( fig 8L) . In accordance with the prebiotic effect, the immunohistochemical staining of both proteins localised along the apical cellular border was higher in Ob-GLP-2 as compared to Ob-CT ( fig 8M) . Therefore, the gut peptide GLP-2 appears as a credible link between gut microbiota, gut permeability, and inflammatory tone.
DISCUSSION
Several reports have demonstrated that the gut microbiota participates in the development of obesity by several mechanisms, ie, by harvesting energy from the diet, by modulating the synthesis of gut peptides involved in energy homeostasis, and/or by regulating fat storage. 63 We have recently demonstrated that mice fed a high-fat diet were characterised by an increase in gut permeability and metabolic endotoxaemia. The inflammatory phenotype of ob/ob mice originates from the gut microbiota, since changing the gut microbiota using antibiotics lowers endotoxaemia-induced inflammation and metabolic disorders. 6 64 65 Recently, it has been proposed that this higher endotoxaemia in ob/ob mice and db/db mice was dependent on a disruption of the key tight-junction proteins, ZO-1 and occludin. 26 Here we confirm that obese mice exhibit an altered gut barrier, characterised by a disruption of tight-junction proteins. Among the mechanisms involved in this phenomenon, excessive TNFa production was proposed to help propagate the extension of a local or systemic inflammation and this inflammatory process per se would trigger the alteration of both junctional proteins. 24 Our data show that prebiotic-fed mice have a lower level of several plasma cytokines well-known to promote tight-junction disruption such as TNFa, IL1b, IL1a, IL6, INFc. [66] [67] [68] [69] In addition, we also found a significant decrease of the chemokines MCP-1 and MIP-1a.
In the present study, we demonstrated, in two separate set of experiments, that changing gut microbiota of ob/ob mice in favour of the Bifidobacterium spp. is associated with a significant improvement of gut permeability measured in vivo; this phenomenon was linked to an increase in tight-junction mRNA expression and proteins distribution. The improved gut barrier observed in prebiotic-fed mice was correlated to the lower portal plasma LPS levels and inflammatory tone (ie, decrease in circulating cytokines). The leakage of gut microbiota-derived LPS into the portal blood is a well-established mechanism of metabolic endotoxaemia that triggers liver inflammation and oxidative stress. 26 70 In the present studies, we found that lowering systemic inflammation by prebiotics is significantly correlated with a strong decrease in markers of oxidative and inflammatory stress in the liver tissue. Altogether, CT, Cell and Pre, respectively, refer to the selected ob/ob mice, fed a normal diet, non-prebiotic control diet or prebiotic diet. GIP, glucose-dependent insulinotropic polypeptide; GLP, glucogon-like peptide. these data strongly suggest that the modulation of the gut microbiota using prebiotics in obese mice, could act favourably on the intestinal barrier, thereby reducing endotoxaemia, systemic and liver inflammation, with beneficial consequences on associated metabolic disorders. However, the mechanisms by which prebiotics improve gut permeability -in the particular context of obesity -are not fully understood. One potential explanation could arise from the putative role of the Bifidobacterium spp in maintaining the gut barrier. Interestingly, Bifidobacterium spp do not degrade intestinal mucus glycoproteins like other pathogenic bacteria do, and Bifidobacterium spp promote a healthier microvillus environment by preventing permeability and bacterial translocation. 71 72 Among the putative mechanisms, it has been demonstrated that the prebiotic modulation of the gut microbiota increases villus height and crypt depth, and leads to a thicker mucosal layer in the jejunum and in the colon. 73 These effects are related to the bacterial fermentation of the prebiotics. The resulting products of fermentation are mainly short-chain fatty acids (SCFAs), with butyrate acting as an energetic substrate for the colonocytes and having a trophic effect on mucosa. 74 75 In epithelial monolayers model, it has been shown that other probiotics strains such as Lactobacillus rhamnosus GG and Lactobacillus casei DN-114-001 protect epithelial barrier function against Escherichia coli-induced redistribution of the tight-junction proteins. 76 77 Besides the putative role of the SCFAs and specific bacterial strains, the exact mechanism underlying the relation between prebiotic-induced changes in gut microbiota and improved gut barrier function has not been described so far.
Here we found that changes in the gut microbiota of ob/ob mice exert a trophic effect on the intestine of Ob-Pre mice, a phenomenon associated with a higher proglucagon mRNA expression in both the jejunum and colon. We have previously demonstrated that prebiotic-induced changes in the gut microbiota promote GLP-1 synthesis (proglucagon mRNA and GLP-1 peptide content) in the proximal colon by a mechanism linked to the differentiation of precursor cells into enteroendocrine cells. 33 44-48 In the present study, we additionally found that changing gut microbiota using prebiotics is associated with an increased endogenous production of the glucagon-like peptide-2 (GLP-2). GLP-2 is a 33 amino acid peptide, formed, as GLP-1, from the cleavage of proglucagon peptide. 57 GLP-2 is associated with intestinal growth and adaptation in a variety of pathological conditions, including post-resection intestinal adaptation, coeliac disease, parental nutrition-induced intestinal atrophy and inflammatory bowel disease. [78] [79] [80] In addition, GLP-2 has also been demonstrated to enhance intestinal adaptation 57 and to reduce the internalisation of enteric bacteria in INT-407 enterocytes in vitro model. 81 Strikingly, the intestinotrophic effects observed following prebiotic administration are similar to the physiological effect of GLP-2. The increased GLP-2 production is in accordance with our earlier study, where we found that changing the gut microbiota of rats fed a high-fat diet following a prebiotic treatment, doubled intestinal GLP-2 concentrations. 46 Besides, here we found that the higher endogenous GLP-2 production is associated with an improvement of the mucosal barrier function, leading to improved tight junctions and decreased plasma LPS concentrations and therefore blunted inflammatory and oxidative stresses. A recent report demonstrates that a chronic treatment with GLP-2 protects rats against the ischaemia-reperfusion-induced endotoxaemia and inflammation, by an unknown mechanism. 82 Our first experiment strongly suggests that the lower metabolic endotoxaemia and the consequent low-grade inflammation observed upon prebiotic feeding could be a mechanism involving an enhanced endogenous GLP-2 production. Indeed, we found that Ob-Pre fed mice exhibited a significant increase of plasma GLP-2 levels and that this parameter negatively correlates with markers of gut permeability. Along the same line, we found a positive correlation between intestinal proglucagon and tight-junction proteins mRNA (ZO-1, occludin). Altogether, these data led us to postulate that the prebiotic-induced intestinal proglucagon mRNA expression and the consequent GLP-2 production may positively impact on gut barrier integrity. Therefore, to investigate this hypothesis, we performed a second set of experiments where we treated mice concomitantly with the prebiotic and a GLP-2 antagonist. First, we confirm the improvement of inflammatory markers following the prebiotic treatment; second, and more importantly, we show that the GLP-2 antagonist completely blocks the major features of the prebiotic treatment. Hence, in absence of GLP-2 signalling, the prebiotic treatment failed to reduce plasma LPS levels, and most of the hepatic inflammatory and oxidative stress markers remained equivalent to the control mice. In addition, the GLP-2 antagonist blocks the positive effects of the prebiotic treatment on both intestinal tightjunction proteins and proglucagon mRNA. Altogether, both set of experiments strongly support that specific changes in gut microbiota improve gut permeability and inflammatory tone by a GLP-2 dependent mechanism.
To support the putative therapeutic effect of GLP-2 in the context of a low-grade inflammation associated with obesity, and in order to delineate the protective role of the GLP-2 independently of the modulation of the gut microbiota, we chronically treated mice with GLP-2. This third set of experiment clearly shows that GLP-2 treatment alone significantly lowers inflammatory tone in obese mice. We found that GLP-2 treated mice exhibited a lower metabolic endotoxaemia, and a lower systemic and hepatic inflammatory tone. These features were associated with a strong positive effect of GLP-2 on the tight-junction proteins distribution. This set of experiments demonstrates that GLP-2 can be useful to treat the altered gut barrier observed in obesity and diabetes, and therefore could lower the inflammatory tone associated with these diseases. It would be interesting to see whether the magnitude of those effects is similar in other models such as diet-induced obesity and diabetes (ie, non-leptin-deficient models).
While the molecular and cellular mechanisms underlying the effect of GLP-2 on the tight junctions and the gut barrier function remained to define, several hypotheses can be postulated. GLP-2 increases the rate of crypt cell proliferation, villus elongation and reduces apoptosis, leading to improved barrier function. 83 It has been proposed that insulin-like growth factor (IGF)-I acts as an essential target of GLP-2. Recent data have shown that mice lacking IGF-I were resistant to GLP-2-induced intestinal growth, crypt-villus height, and crypt cell proliferation. Furthermore, GLP-2 administration increases intestinal IGF-I secretion in vitro and enhances intestinal IGF-I mRNA transcript levels both in vitro and in vivo. 84 In addition to this potential mechanism, data suggest that the downstream molecular mechanism by which GLP-2 receptor activation controls barrier function could be related to the activation of the b-catenin signalling pathway. 39 Nonetheless, further studies are required to fully characterise the mechanisms through which GLP-2 improves gut barrier function.
Together, using the complementary approaches of the specific modulation of the gut microbiota, and of the pharmacological inhibition or activation of the GLP-2 receptor, our findings strongly suggest that GLP-2 participates to the modulation of the gut barrier function and the consequent systemic and hepatic inflammatory phenotype associated with obesity.
In addition, these data demonstrate that a selective modulation of the gut microbiota improves intestinal permeability and inflammatory markers during obesity and diabetes, via an unexpected mechanism such as higher GLP-2 endogenous production.
Thus, we propose that a selective gut microbiota modulation controls and increases endogenous production of the intestinotrophic proglucagon derived peptides GLP-2, and consequently improves gut barrier functions by a GLP-2-dependent mechanism. These new findings demonstrate the usefulness of developing specific therapeutic strategies using GLP-2 to tackle metabolic endotoxaemia and disorders associated with obesity and diabetes, and that gut microbiota modulation could be an interesting tool in this context.
